Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading Volume – What’s Next?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares saw unusually-high trading volume on Friday . Approximately 229,365 shares changed hands during trading, an increase of 29% from the previous session’s volume of 177,694 shares.The stock last traded at $20.11 and had previously closed at $18.99.

Analysts Set New Price Targets

PLSE has been the subject of a number of recent research reports. Oppenheimer initiated coverage on Pulse Biosciences in a research report on Monday, July 7th. They set an “outperform” rating and a $22.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pulse Biosciences currently has a consensus rating of “Hold” and an average target price of $22.00.

Pulse Biosciences Trading Up 1.6%

The business has a 50 day moving average of $16.11 and a two-hundred day moving average of $16.22. The firm has a market cap of $1.30 billion, a P/E ratio of -18.37 and a beta of 1.79.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Insiders Place Their Bets

In other Pulse Biosciences news, CTO Darrin Uecker sold 25,000 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $15.77, for a total transaction of $394,250.00. Following the transaction, the chief technology officer owned 122,872 shares in the company, valued at $1,937,691.44. This trade represents a 16.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin Patrick Danahy sold 20,000 shares of the stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $18.49, for a total value of $369,800.00. Following the transaction, the insider owned 43,298 shares in the company, valued at $800,580.02. The trade was a 31.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,400 shares of company stock worth $1,465,142 in the last 90 days. Company insiders own 74.60% of the company’s stock.

Institutional Trading of Pulse Biosciences

Several large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its holdings in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after purchasing an additional 680 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of Pulse Biosciences by 68.0% during the 1st quarter. AlphaQuest LLC now owns 3,116 shares of the company’s stock worth $50,000 after purchasing an additional 1,261 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Pulse Biosciences by 6.3% during the 1st quarter. Rhumbline Advisers now owns 27,375 shares of the company’s stock worth $440,000 after purchasing an additional 1,614 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Pulse Biosciences by 24.6% during the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company’s stock worth $143,000 after purchasing an additional 1,778 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares in the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.